Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The study is to investigate the safety, tolerability and efficacy of PI3Kδ inhibitor
Parsaclisib in combination with cyclophosphamide, doxorubicin, vincristine and prednisone
(CHOP) in frontline treatment of patients with peripheral T-cell lymphoma (PTCL).